The FDA has approved nivolumab with ipilimumab as a first-line treatment for advanced liver cancer. The U.S. Food and Drug Administration (FDA) has approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the...
NIH layoffs delay research benefiting cancer patients, and celebrity cancer news is often missing important information.
The FDA has approved nivolumab with ipilimumab in certain patients with advanced colorectal cancer. The U.S. Food and Drug Administration (FDA) has approved nivolumab (Opdivo) with ipilimumab (Yervoy) for the treatment of patients 12...
Some early-stage breast cancer patients may not need surgery, and FDA approves Imfinzi for muscle-invasive bladder cancer.
Saliva test can help identify people who are at high risk of recurrence after mouth or throat cancer treatment.
Researchers analyze whether giving immunotherapy before surgery benefits people with high-risk disease that is limited to the liver.
Patients who received Opdivo and chemotherapy had better outcomes and fewer side effects than those who had the standard-of-care therapy.
An experimental antibody helped people recover body mass lost due to cancer and treatment.
Shorter, more intense radiation regimens may be as effective as traditional treatments, with greater convenience for patients.
People with metastatic hormone receptor-positive breast cancer are living longer, thanks to new targeted therapies and endocrine therapies that can be prescribed when treatment resistance develops.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More